Search for: "Roxane Laboratories, Inc."
Results 41 - 55
of 55
Sorted by Relevance
|
Sort by Date
17 Nov 2010, 6:33 pm
Karst – In a November 16th decision that might not mark the end to the dispute between Cody Laboratories, Inc. and Lannett Co., Inc. [read post]
26 Feb 2014, 5:37 pm
Procedural HistoryPlaintiff GlaxoSmithKline LLC (“GSK”) sued Banner Pharmacaps, Inc., Impax Laboratories, Inc., Roxane Laboratories, Inc., Mylan Inc., Mylan Pharmaceuticals, Inc., and Watson Laboratories, Inc. [read post]
10 Nov 2015, 9:16 am
The result of the casePrometheus Laboratories, Inc. [read post]
10 Feb 2010, 4:47 pm
Impax Laboratories Inc. [read post]
19 Jun 2019, 6:18 am
Roxane Laboratories, Inc., et al., No. 18-1280 (obviousness and blocking patents) Hyatt v. [read post]
5 Oct 2010, 2:58 pm
District Court for the District of Columbia’s April 2, 2010 order denying motions for preliminary injunction filed by Roxane Laboratories, Inc. and Apotex. [read post]
19 May 2010, 6:15 am
(Patent Docs) US: CAFC affirms claim construction and corresponding summary judgment of non-infringement: Scantibodies Laboratory, Inc. v. [read post]
21 Jun 2012, 6:52 pm
Shortly before FDA received Lannett’s NDA submission, the Agency, on January 25, 2010, approved a supplement to Roxane Laboratories, Inc. [read post]
4 Aug 2010, 12:21 am
Roxane Laboratories Inc. [read post]
29 Jun 2011, 3:34 am
Roxane Laboratories Inc. et al. [read post]
6 Nov 2011, 10:57 pm
District Court for the District of Wyoming granting FDA’s Motion to Dismiss a lawsuit brought by Cody Laboratories, Inc. and Lannett Co., Inc. [read post]
27 Apr 2010, 10:58 pm
Solstice International Partners et al (Docket Report) US: FTC annual report highlights the Commission’s patent settlement efforts (FDA Law Blog) Products Adcirca (Tadalafil) – US: Declaratory judgement of non-infringement and invalidity based on ANDA to manufacture generic Adcirca: Synthon v Eli Lilly et al (Patent Docs) Amrix (Cyclobenzaprine) – US: Mylan seeks declaratory judgment of noninfringement, unenforceability and invalidity of Amrix patent, based on Mylan’s… [read post]
14 Apr 2010, 12:05 pm
Cir. 2010), and Roxane Laboratories, Inc. has appealed to the D.C. [read post]
10 Sep 2018, 10:17 am
Roxane was that Acorda lost:Roxane Laboratories, Inc.; Mylan Pharmaceuticals,Inc.; and Teva Pharmaceuticals USA, Inc., have submittedAbbreviated New Drug Applications seeking FDAapproval to market generic versions of Ampyra. [read post]
6 Jul 2011, 2:21 am
Biopet Vet Lab, Inc., et. al. [read post]
